merck p53 peptide vaccine patent patent - mens-peptide p53 Merck's P53 Peptide Vaccine Patents: A Deep Dive into Cancer Immunotherapy Innovations

melbourne-peptides The field of cancer treatment is constantly evolving, with a significant focus on harnessing the body's own immune system to combat the disease. Among the most promising avenues of research are p53 peptide vaccines, and Merck's involvement in this area is underscored by numerous patents and ongoing research. The p53 peptide vaccine patent landscape reveals a complex and innovative approach to developing novel cancer therapies, particularly focusing on the critical p53 tumor suppressor protein.

The p53 protein plays a vital role in preventing cancer by regulating cell division and inducing programmed cell death (apoptosis) in cells with damaged DNA. However, mutations in the p53 gene are among the most common genetic alterations found in human cancers, leading to the loss of its protective functions2001年5月30日—Cell permeablepeptideinhibitors that bind to JNK proteins; for inhibiting the JNK-mediated signal transduction pathway. Leadd EP 1 094 110.. This makes p53 and its related pathways attractive targets for therapeutic intervention.

Merck's patent applications and granted patents frequently reference stabilized p53 peptides and uses thereof, as seen in U.S.Targeted MDM2 Degradation Reveals a New Vulnerability for ... Patent No. 9,527,896 B2. These innovations aim to create more effective and durable immune responses against cancer cells expressing specific p53 antigens. The concept behind peptide vaccines is to introduce specific peptide fragments derived from cellular proteins, in this case, p53, to the immune system. This exposure then trains the immune system to recognize and attack cells that display these fragments, particularly cancer cells with mutated or overexpressed p532004年11月17日—The followingpatentapplications are taken from the weekly EuropeanPatentsBulletin and give the publication number and date of ....

Several patents highlight the use of p53 peptide vaccines for the treatment of various cancers.The compound made by the process of the invention is an inhibitor of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and is therefore useful to treat ... For instance, WO 2006/124700, titled "P53 VACCINES FOR THE TREATMENT OF CANCERS," outlines strategies for developing these immunotherapies. Another key patent, U.S.Targeted MDM2 Degradation Reveals a New Vulnerability for ... Patent No. 8,663,646 B2, specifically describes "P53 peptide vaccine," detailing the use of a peptide derived from p53 as a vaccine against cancer. This underscores the direct translation of scientific research into patentable inventions by companies like Merck.

Beyond directly targeting p53, Merck's research also delves into modulating the p53 pathwayP53 activator peptidomimetic macrocycles. One patent application from 2015 mentions a compound that treats cancers by inhibiting Human Double Minute 2 (HDM2) proteins. HDM2 is a known regulator of p53, and its inhibition can lead to increased levels of functional p53, thereby restoring its tumor-suppressive activity. This represents an indirect approach to reactivating the p53 defense mechanism.Peptide vaccine formulations and use thereof for inducing an ...

The development of effective peptide vaccines often involves intricate formulation and delivery strategies.作者：EHC Hsiue·2021·被引用次数：370—Hsiue et al. discovered a way to target a cancer-associated mutant form of thep53protein using the body's own immune system. Patents such as "Peptide vaccine formulations and use thereof for inducing an immune response" touch upon these aspects, aiming to enhance the immunogenicity and therapeutic efficacy of p53-specific vaccines. Research has explored p53 synthetic long peptide vaccines in patients treated for metastatic colorectal cancer, indicating clinical investigations into these approaches.US9527896B2 - Stabilized p53 peptides and uses thereof

The broader field of p53 research also includes other innovative therapeutic strategies that are reflected in patent literature. For example, there are developments in p53 activator peptidomimetic macrocycles that can bind to MDM2 and MDMX, other inhibitors of p53. Furthermore, the concept of mutant p53 peptide pulsed dendritic cell vaccines is being explored, suggesting a sophisticated approach where immune cells are "trained" ex vivo with specific mutant p53 peptide fragments before being reintroduced to the patient.Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor.

The significance of p53 mutations in cancer is widely recognized, with research focusing on targeting these altered proteins. One study highlights targeting a neoantigen derived from a common TP53 mutation using the body's immune system. This approach leverages the unique characteristics of mutant p53 to elicit a targeted immune response.

The patent landscape also reveals collaborations and diverse applications of p53-related technologies.Dimeric Benzodiazepines as Peptide Mimetics to ... For example, Merck has been identified as a top assignee for adenovirus vaccine-related patents, indicating their broad expertise in vaccine development, which can be applied to p53-targeted therapies.

In summary, Merck's p53 peptide vaccine patent portfolio, alongside broader research in the peptide vaccine and p53 therapeutic space, showcases a commitment to advancing cancer immunotherapy. The development of stabilized p53 peptides, strategies to modulate the p53 pathway, and innovative vaccine formulations are all crucial components in the ongoing fight against various forms of cancer. The continuous exploration of p53 as a therapeutic target, through both direct peptide vaccine approaches and indirect modulation, signifies a robust and evolving area of medical innovation.